Chinese medicine stocks in Hong Kong and Hong Kong soared collectively. A-share Zali Pharmaceutical rose more than 16%, Hongri Pharmaceutical rose more than 12%, essence Pharmaceutical, Xintian Pharmaceutical, Jichuan Pharmaceutical, Tongrentang, China Resources Sanjiu, Foci Pharmaceutical, Jianmin Group rose by the daily limit, Dong E E Jiao and Yunnan Baiyao rose more than 5%. Hong Kong stock Tongrentang Technology rose 16%, Chinese traditional medicine rose more than 13%, and Gusheng Tang and Tongrentang rose more than 11%.

National Healthcare Security Administration and the Administration of traditional Chinese Medicine issued the guidance on Medical Insurance to support the inheritance and innovative Development of traditional Chinese Medicine yesterday. Everbright Securities commented: the opinion has increased the protection and support for the development of traditional Chinese medicine from the payment side, which is undoubtedly a heavy dose to strengthen the needle. The development of traditional Chinese medicine has long been an important national strategy, and the introduction of this guidance is of far-reaching significance to fully support and protect the inheritance and innovative development of the traditional Chinese medicine industry with greater strength and determination. The key points are as follows:

1) expand the designated scope of medical insurance, medical treatment in other places can be settled directly, and "Internet +" traditional Chinese medicine services can be included in medical insurance. Designated institutions have been expanded to include traditional Chinese medicine medical institutions, traditional Chinese medicine retail pharmacies, primary medical and rehabilitation hospitals, hospice care centers, nursing homes and pension institutions.

2) strengthen the price management of traditional Chinese medicine services. For the price items of traditional Chinese medicine, optimize the stock, accelerate the new examination and approval, adjust the price dynamically, and focus on the diagnosis and treatment of traditional Chinese medicine. Keep the prepared pieces of traditional Chinese medicine no more than 25% bonus.

3) expand the coverage of medical insurance drugs and characteristic medical services of traditional Chinese medicine. Appropriate pieces of traditional Chinese medicine, proprietary Chinese medicine, traditional Chinese medicine preparations of medical institutions, etc., will be included in the list of medical insurance drugs. All localities are encouraged to bring the appropriate technologies of traditional Chinese medicine that have definite curative effects and reflect the advantages of traditional Chinese medicine into the scope of medical insurance payment.

4) promote the reform of the payment mode of traditional Chinese medical insurance. Medical institutions of traditional Chinese medicine may not pay for DRG for the time being, and appropriately increase the coefficient and score of medical institutions and diseases of traditional Chinese medicine in areas where DRG has been implemented and paid according to the score of diseases.

5) support traditional Chinese medicine services and the sinking of high-quality resources in primary health care institutions. Pay per person is carried out in qualified grass-roots medical and health institutions, and family doctors are encouraged to sign up for services. In terms of the total budget, tilt towards the compact county medical community led by traditional Chinese medicine institutions.